Cancer cell lines are an essential tool of cancer research, but their origin can sometimes be difficult to determine with certainty. In addition to contamination with other cell lines during in vitro cultivation, errors can arise during the initial resection from the patient because the organ of origin can sometimes be difficult to determine. This is particularly problematic for ovarian cancer, where a substantial fraction of the cases represent metastases from distant nongenital sites (1) . Once in culture and without detailed patient data, it can be difficult or impossible to trace the origin of a particular cell population. The difficulty arises from the fact that cells tend to lose their tissue-specific markers during tumorigenesis and in vitro establishment.
In the course of our study of ␤-catenin signaling in ovarian cancer, we discovered several ovarian cancer lines that have constitutively elevated ␤-catenin-mediated transcription (Furlong MT, Morin PJ: unpublished results). Deregulation of this pathway results in inappropriate activation of T-cell factor-responsive genes and, in colon cancer, is due to mutations either in ␤-catenin or in the tumor suppressor gene adenomatous polyposis coli (APC) (2, 3) . Our finding of ovarian cell lines with an activated ␤-catenin/T-cell factor pathway is consistent with a recent report (4) that ␤-catenin is mutated in a subset of ovarian cancers. SW626, a well-studied ovarian cancer cell line, showed high levels of ␤-cateninmediated transcriptional activation but contained a wild-type ␤-catenin gene, as assessed by direct sequencing. Surprisingly, however, when a cell lysate of SW626 was probed by immunoblotting with an anti-APC antibody, full-length APC was not detected (Fig. 1, A) . Instead, SW626 expressed a truncated product of approximately 110 kd. The APC tumor suppressor gene is mutated in the vast majority of all colon cancers (5) but has never been found to be altered in ovarian cancer. Indeed, APC was previously analyzed in 40 sporadic ovarian carcinomas, and no mutations were found (6) .
To identify the APC mutation present in SW626, part of exon 15 was amplified from genomic DNA by the polymerase chain reaction, and the purified fragment was used as a template for direct sequencing. An insertion of one adenine in a tract of four consecutive adenines was found in the APC gene at nucleotide 2941 (A2941) (Fig. 1, B) . The A2941 insertion is predicted to produce a frameshift along with the generation of an in-frame termination codon nine amino acids downstream of the adenine tract. This mutation was not found in the human gene mutation database (7) but is reminiscent of a type of mutation frequently found in colon cancer (8) . It is interesting that no wild-type sequence was present, strongly suggesting hemizygosity at the APC locus. This finding is consistent with the observation that no full-length Apc protein was detected by immunoblotting ( Fig. 1, A) . As a control, the same region of APC was sequenced from ovarian cancer cell line A2780 and was found to be wild type (Fig. 1, B) . To rule out possible contamination with a colon cancer cell line in our laboratory or at the American Type Culture Collection (Manassas, VA), an SW626 seed stock was obtained from the American Type Culture Collection, and genomic DNA was prepared directly from the frozen cells without cultivation. APC exon 15 was amplified and sequenced as described above. The A2941 insertion was present, demonstrating that this mutation is not the result of an in vitro culturing contamination.
Because the above results suggested that SW626 may be of colonic origin, we decided to investigate this issue further by using immunologic markers often used to differentiate ovarian from colonic primary tumors. SW626 cells were stained with antibodies against cytokeratin (CK) 20, CK7, estrogen receptor/progesterone receptor, CA125, carcinoembryonic antigen, and Calretinin. It has been reported that CK20 and CK7 are the best markers to differentiate colonic from ovarian carcinoma (9, 10) . Typically, colonic carcinomas are positive for CK20 and negative for CK7; in contrast, ovarian carcinomas are usually positive for CK7 and negative for CK20. The staining pattern of SW626 was completely consistent with a colonic origin because it was positive for CK20 Correspondence to: Patrice J. Morin, Ph.D., Laboratory of Biological Chemistry, Gerontology Research Center, National Institute on Aging, 5600 Nathan Shock Dr., Baltimore, MD 21224 (e-mail: morinp@grc.nia.nih.gov).
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© Oxford University Press and negative for CK7 (Table 1) . These staining data were confirmed by examining the results of an ongoing serial analysis of gene expression (11) in our laboratory. The CK20 transcript was found at relatively high levels in SW626 (0.1% of the total messenger RNAs), whereas the CK7 messenger RNA was not detected in more than 5000 transcripts. The other markers shown in Table 1 are not as consistently reliable for differentiating ovarian from colonic carcinomas but are still of interest. Estrogen receptor/progesterone receptor, CA125, and Calretinin, which are sometimes positive in ovarian cancer, were negative in SW626, and carcinoembryonic antigen, a marker that is positive in up to 50% of colon cancer specimens (10), was negative in SW626. Our results suggest that SW626 is a cell line of colonic origin. Because of their ability to mimic ovarian primary tumors, colonic carcinomas that have metastasized to the ovaries can be misclassified as ovarian primary tumors (12, 13) . We suggest the possibility that SW626 may have been misdiagnosed when it was first resected in 1974. This may explain unusual findings in our laboratory and other laboratories, including one report (14) describing the expression of the gastrointestinal tract protein gastrin in SW626. It is impossible to clearly establish the origin of a cell line after many years in culture. At the very least, the data presented herein demonstrate that SW626 does not represent a "typical" ovarian cancer and would suggest caution when this cell line is used.
NOTE
Manuscript received December 28, 1998; revised May 14, 1999; accepted June 8, 1999. Negative Negative Positive *Colon and ovarian data represent the typical expression pattern observed in these cancers. Immunohistochemical localization of target antigens in deparaffinized 8-m sections of SW626 cells was performed on the BioTek 1000™ automated immunostainer and the BioTek 1000 kit (Bio-Tek Instruments, Inc., Burlington, VT) after heatinduced epitope retrieval. Incubation with primary antibodies (below) was followed by sequential incubation with biotinylated goat anti-mouse or goat anti-rabbit antibodies, avidin-horseradish peroxidase, and 3,3Ј-diaminobenzidine as the chromagen with a hematoxylin counterstain. Primary antibodies were diluted according to the specifications of the suppliers: cytokeratin (CK) 7 and 20, carcinoembryonic antigen (CEA), and progesterone receptor (PR) (Dako Corp., Carpinteria, CA), estrogen receptor (ER) (Immunotech, Westbrook, ME), CA125 (Signet, Dedham, MA), and Calretinin (Zymed Laboratories Inc., South San Francisco, CA). †Less reliable.
